Halftime Report | Big Boost For Biocon | Rcvs US FDA Nod | CNBC TV18

Описание: Biocon and its partner Mylan on Tuesday said they had got USFDA approval for Fulphila or Pegfilgrastim.

Pegfilgrastim is a biosimilar version of Amgen’s Neulasta used to stimulate the level of neutrophils, a type of white blood cell that gets damaged in cancer patients undergoing chemotherapy. Biocon-Mylan's Fulphila is the first FDA-approved biosimilar to Neulasta and the second biosimilar from Mylan and Biocon's joint portfolio approved in the US.

CNBC-TV18 is India's No.1 Business medium and the undisputed leader in business news. The channel's benchmark coverage extends from corporate news, financial markets coverage, expert perspective on investing and management to industry verticals and beyond. CNBC-TV18 has been constantly innovating with new genres of programming that helps make business more relevant to different constituencies across India. India's most able business audience consumes CNBC-TV18 for their information & investing needs. This audience is highly diversified at one level comprising of key groups such as business leaders, professionals, retail investors, brokers and traders, intermediaries, self-employed professionals, High Net Worth individuals, students and even homemakers but shares a distinct commonality in terms of their spirit of enterprise.

Subscribe to our Channel: https://goo.gl/hKwgtm
Like us on Facebook:   / cnbctv18india  
Follow us on Twitter:   / cnbctv18news  
Website: http://www.moneycontrol.com/cnbctv18/